PCSK9 and atherosclerosis: Consequently, lowering plasma levels of low-density lipoprotein cholesterol (LDL-C), which is still the foundation in atherosclerosis treatment, by the inhibition of PCSK9 activity presents a promising therapeutic target (5–11).